<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0409245858
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TORICOX 120MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Etoricoxib
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        120
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        15.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M01AH05 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What is Toricox&trade;?<br />Toricox&trade; contains the active substance etoricoxib. Toricox&trade; is one of a group of<br />medicines called selective COX-2 inhibitors. These belong to a family of medicines called<br />non-steroidal anti-inflammatory drugs (NSAIDs).<br />What is Toricox&trade; used for?<br />Toricox&trade; helps to reduce the pain and swelling (inflammation) in the joints and muscles<br />of people 16 years of age and older with osteoarthritis, rheumatoid arthritis, ankylosing<br />spondylitis and gout.<br />Toricox&trade; is also used for the short term treatment of moderate pain after dental surgery in<br />people 16 years of age and older.<br />What is osteoarthritis?<br />Osteoarthritis is a disease of the joints. It results from the gradual breakdown of cartilage<br />that cushions the ends of the bones. This causes swelling (inflammation), pain, tenderness,<br />stiffness and disability.<br />What is rheumatoid arthritis?<br />Rheumatoid arthritis is a long term inflammatory disease of the joints. It causes pain,<br />stiffness, swelling, and increasing loss of movement in the joints it affects. It may also<br />cause inflammation in other areas of the body.<br />What is gout?<br />Gout is a disease of sudden, recurring attacks of very painful inflammation and redness in<br />the joints. It is caused by deposits of mineral crystals in the joint.<br />What is ankylosing spondylitis?<br />Ankylosing spondylitis is an inflammatory disease of the spine and large joints.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Toricox&trade;:<br />&bull; if you are allergic (hypersensitive) to etoricoxib or any of the other ingredients of this<br />medicine (listed in section 6)<br />&bull; if you are allergic to non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin<br />and COX-2 inhibitors (see Possible Side Effects, section 4)<br />&bull; if you have a current stomach ulcer or bleeding in your stomach or intestines<br />&bull; if you have serious liver disease<br />&bull; if you have serious kidney disease<br />&bull; if you are or could be pregnant or are breast-feeding (see &lsquo;Pregnancy, breast feeding, and<br />fertility&rsquo;)<br />&bull; if you are under 16 years of age<br />&bull; if you have inflammatory bowel disease, such as Crohn&rsquo;s Disease, Ulcerative Colitis, or<br />Colitis<br />&bull; if you have high blood pressure that has not been controlled by treatment (check with<br />your doctor or nurse if you are not sure whether your blood pressure is adequately<br />controlled)<br />&bull; if your doctor has diagnosed heart problems including heart failure (moderate or severe<br />types), angina (chest pain)<br />&bull; if you have had a heart attack, bypass surgery, peripheral arterial disease (poor circulation<br />in legs or feet due to narrow or blocked arteries)<br />&bull; if you have had any kind of stroke (including mini-stroke, transient ischaemic attack or<br />TIA). Etoricoxib may slightly increase your risk of heart attack and stroke and this is why<br />it should not be used in those who have already had heart problems or stroke.<br />If you think any of these are relevant to you, do not take the tablets until you have<br />consulted your doctor.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Toricox&trade; if:<br />&bull; You have a history of stomach bleeding or ulcers.<br />&bull; You are dehydrated, for example by a prolonged bout of vomiting or diarrhoea.<br />&bull; You have swelling due to fluid retention.<br />&bull; You have a history of heart failure, or any other form of heart disease.<br />&bull; You have a history of high blood pressure. Toricox&trade; can increase blood pressure in<br />some people, especially in high doses, and your doctor will want to check your blood<br />pressure from time to time.<br />&bull; You have any history of liver or kidney disease.<br />&bull; You are being treated for an infection. Toricox&trade; can mask or hide a fever, which is a<br />sign of infection.<br />&bull; You have diabetes, high cholesterol, or are a smoker. These can increase your risk of<br />heart disease.<br />&bull; You are a woman trying to become pregnant.<br />&bull; You are over 65 years of age.<br />If you are not sure if any of the above apply to you, talk to your doctor before taking<br />Toricox&trade; to see if this medicine is suitable for you.<br />Toricox&trade; works equally well in older and younger adult patients. If you are over 65 years<br />of age, your doctor will want to appropriately keep a check on you. No dosage adjustment<br />is necessary for patients over 65 years of age.<br />Children and adolescents<br />Do not give this medicine to children and adolescents under 16 years of age.<br />Other medicines and Toricox&trade;<br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any<br />other medicines, including medicines obtained without a prescription.<br />In particular if you are taking any of the following medicines, your doctor may want to<br />monitor you to check that your medicines are working properly, once you start taking<br />Toricox&trade;:<br />&bull; medicines that thin your blood (anticoagulants), such as warfarin<br />&bull; rifampicin (an antibiotic)<br />&bull; methotrexate (a drug used for suppressing the immune system, and often used in<br />rheumatoid arthritis)<br />&bull; ciclosporin or tacrolimus (drugs used for suppressing the immune system)<br />&bull; lithium (a medicine used to treat some types of depression)<br />&bull; medicines used to help control high blood pressure and heart failure called ACE<br />inhibitors and angiotensin receptor blockers, examples include enalapril and ramipril, and<br />losartan and valsartan<br />&bull; diuretics (water tablets)<br />&bull; digoxin (a medicine for heart failure and irregular heart rhythm)<br />&bull; minoxidil (a drug used to treat high blood pressure)<br />&bull; salbutamol tablets or oral solution (a medicine for asthma)<br />&bull; birth control pills (the combination may increase your risk of side effects)<br />&bull; hormone replacement therapy (the combination may increase your risk of side effects)<br />&bull; aspirin, the risk of stomach ulcers is greater if you take Toricox&trade; with aspirin.<br />- aspirin for prevention of heart attacks or stroke:<br />Toricox&trade; can be taken with low-dose aspirin. If you are currently taking low-dose aspirin<br />to prevent heart attacks or stroke, you should not stop taking aspirin until you talk to your<br />doctor<br />- aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs):<br />do not take high dose aspirin or other anti-inflammatory medicines while taking<br />Toricox&trade;.<br />Toricox&trade; with food and drink<br />The onset of the effect of Toricox&trade; may be faster when taken without food.<br />Pregnancy, breast-feeding, and fertility<br />Pregnancy<br />Toricox&trade; tablets must not be taken during pregnancy. If you are pregnant or think you<br />could be pregnant, or if you are planning to become pregnant, do not take the tablets. If<br />you become pregnant, stop taking the tablets and consult your doctor. Consult your doctor<br />if you are unsure or need more advice.<br />Breast-feeding<br />It is not known if Toricox&trade; is excreted in human milk. If you are breast-feeding, or<br />planning to breast-feed, consult your doctor before taking Toricox&trade;. If you are using<br />Toricox&trade;, you must not breast-feed.<br />Fertility<br />Toricox&trade; is not recommended in women attempting to become pregnant.<br />Driving and using machines<br />Dizziness and sleepiness have been reported in some patients taking Toricox&trade;. Do not<br />drive if you experience dizziness or sleepiness.<br />Do not use any tools or machines if you experience dizziness or sleepiness.<br />Toricox&trade; contains lactose<br />If you have been told by your doctor that you are unable to tolerate some sugars, contact<br />your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with<br />your doctor or pharmacist if you are not sure.<br />Do not take more than the recommended dose for your condition. Your doctor will want to<br />discuss your treatment from time to time. It is important that you use the lowest dose that<br />controls your pain and you should not take Toricox&trade; for longer than necessary. This is<br />because the risk of heart attacks and strokes might increase after prolonged treatment,<br />especially with high doses.<br />There are different strengths available for this medicinal product and depending on your<br />disease your doctor will prescribe the tablet strength that is appropriate for you.<br />The recommended dose is:<br />Osteoarthritis<br />The recommended dose is 30 mg once a day, increase to a maximum of 60 mg once a day<br />if needed.<br />Rheumatoid arthritis<br />The recommended dose is 60 mg once a day, increased to a maximum of 90 mg once a day<br />if needed.<br />Ankylosing spondylitis<br />The recommended dose is 60 mg once a day, increased to a maximum of 90 mg once a day<br />if needed.<br />Acute pain conditions<br />Etoricoxib should be used only for the acute painful period.<br />Gout<br />The recommended dose is 120 mg once a day which should only be used for the acute<br />painful period, limited to a maximum of 8 days treatment.<br />Postoperative dental surgery pain<br />The recommended dose is 90 mg once daily, limited to a maximum of 3 days treatment.<br />People with liver problems<br />&bull; If you have mild liver disease, you should not take more than 60 mg a day.<br />&bull; If you have moderate liver disease, you should not take more than 30 mg a day.<br />Use in children and adolescents<br />Toricox&trade; tablets should not be taken by children or adolescents under 16 years of age.<br />Elderly<br />No dose adjustment is necessary for elderly patients. As with other medicines, caution<br />should be exercised in elderly patients.</p><p>Method of administration<br />Toricox&trade; is for oral use. Take the tablets once a day. Toricox&trade; can be taken with or<br />without food.<br />If you take more Toricox&trade; than you should<br />You should never take more tablets than the doctor recommends. If you do take too many<br />Toricox&trade; tablets, you should seek medical attention immediately.<br />If you forget to take Toricox&trade;<br />It is important to take Toricox&trade; as your doctor has prescribed. If you miss a dose, just<br />resume your usual schedule the following day. Do not take a double dose to make up for<br />the forgotten tablet.<br />If you have any further questions on the use of this medicine, ask your doctor or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If you develop any of these signs you should stop Toricox&trade; and talk to your doctor<br />immediately (see What you need to know before you take Toricox&trade;<br />section 2):<br />&bull; shortness of breath, chest pains, or ankle swelling appear or if they get worse<br />&bull; yellowing of the skin and eyes (jaundice)-these are signs of liver problems<br />&bull; severe or continual stomach pain or your stools become black<br />&bull; an allergic reaction- which can include skin problems such as ulcers or blistering, or<br />swelling of the face, lips, tongue, or throat which may cause difficulty in breathing<br />The frequency of possible side effects listed below is defined using the following<br />convention: Very common (affects more than 1 user in 10)<br />Common (affects 1 to 10 users in 100) Uncommon (affects 1 to 10 users in 1,000) Rare<br />(affects 1 to 10 users in 10,000)<br />Very rare (affects less than 1 user in 10,000)<br />The following side effects can occur during treatment with Toricox&trade;:<br />Very Common:<br />&bull; stomach pain<br />Common:<br />&bull; dry socket (inflammation and pain after a tooth extraction)<br />&bull; swelling of the legs and/or feet due to fluid retention (oedema)<br />&bull; dizziness, headache<br />&bull; palpitations (fast or irregular heartbeat), irregular heart rhythm (arrhythmia)<br />&bull; increased blood pressure<br />&bull; wheezing or shortness of breath (bronchospasms)<br />&bull; constipation, wind (excessive gas), gastritis (inflammation of the lining of the stomach),<br />heartburn, diarrhoea, indigestion (dyspepsia)/stomach discomfort, nausea, being sick<br />(vomiting), inflammation of the oesophagus, mouth ulcers<br />&bull; changes in blood tests related to your liver<br />&bull; bruising<br />&bull; weakness and fatigue, flu-like illness<br />Uncommon:<br />&bull; gastroenteritis (inflammation of the gastrointestinal tract that involves both the stomach<br />and small intestine/stomach flu), upper respiratory infection, urinary tract infection<br />&bull; changes in laboratory values (decreased number of red blood cells, decreased number of<br />white blood cells, platelets decreased)<br />&bull; hypersensitivity (an allergic reaction including hives which may be serious enough to<br />require immediate medical attention)<br />&bull; appetite increases or decreases, weight gain<br />&bull; anxiety, depression, decreases in mental sharpness; seeing, feeling or hearing things that<br />are not there (hallucinations)<br />&bull; taste alteration, inability to sleep, numbness or tingling, sleepiness<br />&bull; blurred vision, eye irritation and redness<br />&bull; ringing in the ears, vertigo (sensation of spinning while remaining still)<br />&bull; abnormal heart rhythm (atrial fibrillation), fast heart rate, heart failure, feeling of<br />tightness, pressure or heaviness in the chest (angina pectoris), heart attack<br />&bull; flushing, stroke, mini-stroke (transient ischaemic attack), severe increase in blood<br />pressure, inflammation of the blood vessels<br />&bull; cough, breathlessness, nose bleed<br />&bull; stomach or bowel bloating, changes in your bowel habits, dry mouth, stomach ulcer,<br />inflammation of the stomach lining that can become serious and may lead to bleeding,<br />irritable bowel syndrome, inflammation of the pancreas<br />&bull; swelling of the face, skin rash or itchy skin, redness of the skin<br />&bull; muscle cramp/spasm, muscle pain/stiffness<br />&bull; high levels of potassium in your blood, changes in blood or urine tests relating to your<br />kidney, serious kidney problems<br />&bull; chest pain<br />Rare:<br />&bull; angioedema (an allergic reaction with swelling of the face, lips, tongue and/or throat<br />which may cause difficulty in breathing or swallowing, which may be serious enough to<br />require immediate medical attention)/anaphylactic/anaphylactoid reactions including shock<br />(a serious allergic reaction that requires immediate medical attention)<br />&bull; confusion, restlessness<br />&bull; liver problems (hepatitis)<br />&bull; low blood levels of sodium<br />&bull; liver failure, yellowing of the skin and/or eyes (jaundice)<br />&bull; severe skin reactions<br />Reporting of side effects<br />If you get any side effects, talk to your doctor or pharmacist. This includes any possible<br />side effects not listed in this leaflet. By reporting side effects, you can help provide more<br />information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.<br />Do not store above 30 &ordm;C.<br />Do not use this medicine after the expiry date which is stated on the carton.<br />Bottles: Keep the container tightly closed in order to protect from moisture. Blisters: Store<br />in the original package in order to protect from moisture.<br />Do not throw away any medicines via wastewater or household waste. Ask your<br />pharmacist how to throw away medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Toricox&trade; contains:<br />Each film coated tablets contains 60 / 90 /120 mg of Etoricoxib.<br />Other ingredients are:<br />Contains:<br />Anhydrous Dibasic Calcium Phosphate, Microcrystalline Cellulose, Povidone,<br />Croscarmellose Sodium, Magnesium Stearate.<br />Coating content:<br />For 60 mg :Opadry II Green 32K210018 (Which Contains Hypromellose, Lactose<br />monohydrate,Titanium dioxide, Triacetin, Yellow Iron Oxide ,Fd&amp;C Blue #2/Indigo<br />Carmine Aluminum Lake)<br />For 90 mg : Opadry II White - 32K280000 (Which Contains Hypromellose, Lactose<br />monohydrate,Titanium dioxide, Triacetin)<br />For 120 mg : Opadry II Green 32K510003 (Which Contains Hypromellose, Lactose<br />monohydrate,Titanium dioxide, Triacetin, Yellow Iron Oxide ,Fd&amp;C Blue #2/Indigo<br />Carmine Aluminum Lake).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Toricox™ 60 mg : Dark green colored, round, biconvex, film coated tablets debossed with
''JP'' on one side and ''AK'' on other side.
Toricox™ 90 mg :White colored, round, biconvex, film coated tablets debossed with ''JP''
on one side and ''AL'' on other side.
Toricox™ 120 mg :Pale green colored, round, biconvex, film coated tablets debossed with
''JP'' on one side and ''167'' on other side.
Toricox™ 60 mg available in a carton of 3 x 10’s blisters.
Toricox™ 90 mg available in a carton of 3 x 10’s blisters.
Toricox™ 120 mg available in a carton of 1 x 10’s blisters.
Not all packs may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co.,<br />Jeddah, Saudi Arabia.<br />Tel: +966-12-6081111,<br />Fax: +966-12-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and<br />Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>وفيما يُستخدم؟ ؟&trade; ۱. ما هو توريكوكس<br />؟&trade; ما هو توريكوكس<br />إلى ملجموعة أدوية تُسَمَّى &trade; على المادة الفعالة إتوريكوكسيب، وينتمي توريكوكس &trade; يحتوي توريكوكس<br />۲) والتي تنتمي لفئة أدوية تُسمَّى مضادات الالتهاب غير -COX) المثبطات الانتقائية لإنزيم الأكسدة الحلقية- ۲<br />.(NSAIDs) الستيرويدية<br />؟&trade; فيما يُستخدَم توريكوكس<br />على تخفيف الألم والتورم (الالتهاب) في المفاصل والعضلات لمرضى التهاب المفاصل &trade; يساعد توريكوكس<br />والتهاب المفاصل الروماتويدي والتهاب الفقرات التيبسي والنقرس، الذين يبلغ عمرهم ۱٦ عامًا أو أكثر.<br />لفترة قصيرة لعلاج الألم المتوسط الناجم عن الخضوع لجراحة في الأسنان للمرضى &trade; كما يُستخدَّم توريكوكس<br />الذين يبلغ عمرهم ۱٦ عامًا أو أكثر.<br />ما هو التهاب المفاصل؟<br />التهاب المفاصل عبارة عن مرض يصيب المفاصل وينجم عن تكسر تدريجي في الغضروف الذي يغطي<br />أطراف العظام؛ مما يسبب تورم (التهاب) وألم ووجع عند الضغط على المنطقة المصابة وتصلب وعجز عن<br />الحركة.<br />ما هو التهاب المفاصل الروماتويدي؟<br />التهاب المفاصل الروماتويدي عبارة عن مرض التهابي طويل الأمد يصيب المفاصل. يسبب ألم وتصلب وتورم<br />ويقلل قدرة المفاصل التي يصيبها على الحركة. قد يؤدي أيضًا إلى التهاب أجزاء أخرى من الجسم.<br />ما هو النقرس؟<br />النقرس عبارة عن مرض يظهر على هيئة نوبات التهاب شديد الألم مفاجئة ومتكررة مصاحَبة باحمرار في<br />المفاصل. ينجم النقرس عن تراكم ترسيبات البلورات المعدنية الموجودة في المفصل.<br />ما هو التهاب الفقرات التيبسي؟<br />التهاب الفقرات التيبسي عبارة عن مرض التهابي يصيب العمود الفقري والمفاصل الكبيرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۲. ما تحتاج إلى معرفته قبل تناوُل توريكوكس<br />في الحالات التالية &trade; لا تتناول توريكوكس<br />&bull; إذا كنت تعاني من حساسية (فرط حساسية) تجاه إتوريكوكسيب أو أي مكون من المكونات الأخرى الداخلة في<br />.( تركيب هذا الدواء (المدرجة في قسم ٦<br />&bull; إذا كنت تعاني من حساسية تجاه الأدوية المضادة للالتهاب غير الستيرويدية، بما فيها أسبرين ومثبطات إنزيم<br />.( الأكسدة الحلقية- ۲ (انظر الآثار الجانبية المحتملة، قسم ٤<br />&bull; إذا كُنت حاليًا مصابًا بقُرحة أو بنزيف في المعدة أو الأمعاء.<br />&bull; إذا كنت مصابًا بمرض كبدي خطير.<br />&bull; إذا كنت مصابًا بمرض كلوي خطير.<br />&bull; إذا كنتِ حاملًا أو قد تصبحين حاملاً أو تمارسين الرضاعة الطبيعية (انظري &quot;الحمل والرضاعة الطبيعية<br />والخصوبة&quot;).<br />&bull; إذا كان عمرك يقل عن ۱٦ عامًا.<br />&bull; إذا كنت مصابًا بمرض التهابي في الأمعاء، مثل: مرض كرون أو التهاب القولون التَّقرحي أو التهاب القولون.<br />&bull; إذا كنت تعاني من ارتفاع ضغط الدم الذي يعجز العلاج عن التحكم فيه (يُرجى الرجوع إلى الطبيب المعالج<br />لك أو الممرض(ة) المتابع(ة) لك إذا لم تكن متأكدًا ما إذا كان ضغط الدم لديك يتم التحكم فيه بشكل جيد أم لا).<br />&bull; إذا تم تشخيصك من قبل طبيبك بإصابتك بمشكلات في القلب بما فيها قصور القلب (الأنواع المتوسطة أو<br />الشديدة) أو ذبحة صدرية (ألم في الصدر).<br />&bull; إذا عانيت من نوبة قلبية أو أجريت جراحة تركيب مجازة (تغيير شرايين القلب) أو إذا كنت مصابًا بمرض في<br />الشرايين الطرفية (سوء توزيع الدم في الساقين أو القديم نتيجة ضيق الشرايين أو انسدادها)<br />&bull; إذا عانيت من سكتة دماغية (بما في ذلك سكتة دماغية صغرى أو نوبة إقفارية مؤقتة). قد يزيد إتوريكوكسيب<br />خطر التعرض لنوبة قلبية وسكتة دماغية زيادة طفيفة، لذا يجب ألا يتناوله المرضى الذين أصيبوا باضطرابات<br />في القلب أو سكتة دماغية.<br />إذا كنت تعتقد أن أيٍّ من هذه الأعراض ينطبق عليك، فلا تتناول الأقراص إلا بعد استشارة الطبيب المعالج لك.<br />تحذيرات واحتياطات<br />في الحالات التالية: ،&trade; تحدث إلى الطبيب المعالج لك أو الصيدلي الخاص بك قبل تناول توريكوكس<br />&bull; إذا كان لديك تاريخ من الإصابة بنزيف أو تقرحات في المعدة.<br />&bull; إذا كنت تعاني من الجفاف، مثلًا الناجم عن نوبة طويلة من القيء أو الإسهال.<br />&bull; إذا كنت مصابًا بتورم نتيجة احتباس السوائل.<br />&bull; إذا كان لديك تاريخ من الإصابة بفشل القلب أو أي مرض في القلب.<br />ضغط الدم لدى بعض الأشخاص، &trade; &bull; إذا كان لديك تاريخ مرضي من ارتفاع ضغط الدم. قد يرفع توريكوكس<br />خاصة عند تناول جرعات مرتفعة، وسوف يرغب الطبيب المعالج لك في قياس ضغط دمك من وقت لآخر.<br />&bull; إذا كان لديك تاريخ مرضي من الإصابة بأمراض في الكبد أو الكلى.<br />الحمى، وهي علامة على الإصابة بعدوى. &trade; &bull; إذا كنت تتلقى علاجًا لعدوى ما. قد يُخفي أو يحجب توريكوكس<br />&bull; إذا كنت مصابًا بمرض السكري أو ارتفاع مستوى الكوليسترول في الدم أو إذا كنت من المدخنين. وقد تُزيد<br />هذه الحالات من تعرضك لأمراض القلب.<br />&bull; إذا كنتِ تحاولين أن تصبحين حاملًا.<br />&bull; إذا كان عمرك ٦٥ عامًا أو أكثر.<br />إذا لم تكن متأكدًا مما إذا كان ينطبق عليك أيًّا مما سبق، فيُرجى التحدث إلى الطبيب المعالج لك قبل تناول<br />لتعرف ما إذا كان هذا الدواء ملائمًا لك. &trade; توريكوكس<br />بين المرضى البالغين سواء الكبار أم الصغار. قد يحتاج الطبيب المعالج لك إلى &trade; لا تختلف فعالية توريكوكس<br />فحصك بصورة منتظمة إذا كان عمرك يزيد عن ٦٥ عامًا. ولا داعي لتعديل الجرعة للمرضى الذين يزيد<br />عمرهم عن ٦٥ عامًا.<br />الأطفال والمراهقون<br />لا يُستخدَّم هذا الدواء للمرضى من الأطفال والمراهقين الذين تقل أعمارهم عن ۱٦ عامًا.<br />&trade; تناوُل أدوية أخرى مع توريكوكس<br />يُرجى إبلاغ الطبيب المعالج لك أو الصيدلي المتابع لك ما إذا كنت تتناول أو تناولت مؤخرًا أو قد تناولت أيَّة<br />أدوية أخرى، بما في ذلك الأدوية التي حصلت عليها دون وصفة طبية.<br />إذا كنت تتناول أيًّا من الأدوية التَّالية على وجه الخصوص، فقد يرغب الطبيب المعالج لك في متابعة حالتك؛<br />:&trade; للتَّأكد من عمل الأدوية التي تتناولها بشكل صحيح، بمجرد بدء علاجك بتوريكوكس<br />&bull; الأدوية المسيلة للدم (مضادات التخثر)، مثل وارفارين.<br />&bull; ريفامبيسين (مضاد حيوي).<br />&bull; ميثوتريكسات (دواء يُستخدَم في كبت جهاز المناعة وغالبًا يُستخدم في علاج التهاب المفاصل الروماتويدي).<br />&bull; ميثوتريكسات (دواء يُستخدَم في كبت جهاز المناعة).<br />&bull; ليثيوم (دواء يُستَخدَم لعلاج بعض أنواع الاكتئاب).<br />&bull; الأدوية التي تستخدم للتحكم في ضغط الدم وفشل القلب، وتسمي مثبطات الإنزيم المحول للأنجيوتنسين<br />وحاصرات مستقبلات الأنجيوتينسين، مثل إنالابريل وراميبريل ولوسارتان وفالسارتان.<br />&bull; مدرات البول (أقراص الماء).<br />&bull; ديجوكسين (دواء لعلاج فشل القلب وعدم انتظام ضربات القلب).<br />&bull; مينوكسيديل (دواء يستخدم لعلاج ارتفاع ضغط الدم).<br />&bull; سالبوتامول أقراص أو محلول فموي (دواء لعلاج الربو).<br />&bull; حبوب منع الحمل (قد يزيد تناولها مع العقار من خطر التعرض لآثار جانبية).<br />&bull; العلاج بالهرمونات البديلة (قد يزيد تناولها مع العقار من خطر التعرض لآثار جانبية).<br />مع الأسبرين. &trade; &bull; الأسبرين، يزيد من خطر الإصابة بتقرحات المعدة عند تناول توريكوكس<br />- تناوُل أسبرين للوقاية من الإصابة بنوبة قلبية أو سكتة دماغية:<br />مع جرعة منخفضة من أسبرين. إذا كنت تتناول حاليًّا جرعة منخفضة من أسبرين &trade; يمكن تناوُل توريكوكس<br />للوقاية من النوبات القلبية أو السكتات الدماغية، يجب عليك أن تتوقف عن تناول الأسبرين حتى تستشر الطبيب<br />المعالج لك في هذا الأمر.<br />:(NSAIDs) أسبرين والأدوية المضادة للالتهابات غير الستيرويدية<br />.&trade; يجب عدم تناول جرعة مرتفعة من أسبرين أو الأدوية المضادة للالتهابات مع توريكوكس<br />مع الطعام والمشروبات &trade; تناوُل توريكوكس<br />في الظهور بشكل أسرع إذا تم تناوله بدون طعام. &trade; قد يبدأ مفعول توريكوكس<br />الحمل والرضاعة الطبيعية والخصوبة<br />الحمل<br />أثناء فترة الحمل. وإذا كنتِ حاملًا أو تعتقدين أنكِ حاملاً أو إذا كنتِ تنوين أن &trade; يجب عدم تناول توريكوكس<br />تصبحي حاملًا. يجب عليكِ التوقف عن تناول الأقراص واستشارة الطبيب المعالج لكِ إذا أصبحتِ حاملًا.<br />استشيري الطبيب المعالج لكِ إذا راودتكِ أي شكوك أو كنت تريدين معرفة المزيد من المعلومات.<br />الرضاعة الطبيعية<br />في لبن الأم أم لا. يجب عليكِ استشارة الطبيب المعالج لك &trade; من غير المعروف ما إذا كان يتم إفراز توريكوكس<br />وإذا كنتِ مرضعًا أو تنوين ممارسة الرضاعة الطبيعية. يجب عليكِ ألا تمارسي &trade; قبل تناول توريكوكس<br />.&trade; الرضاعة إذا كنتِ تتناولين توريكوكس<br />الخصوبة<br />للسيدات اللاتي يحاولن الحمل. &trade; لا يُنصَح باستخدام توريكوكس<br />القيادة واستخدام الآلات<br />بدوخة ونعاس، ولذلك يجب عدم القيادة في &trade; تم الإبلاغ عن إصابة بعض المرضى الذين يتناولون توريكوكس<br />حالة الشعور بدوخة أو نعاس.<br />يجب عدم استخدام أي أدوات أو تشغيل آلات في حالة الشعور بدوخة أو نعاس.<br />على سكر اللاكتوز &trade; يحتوي توريكوكس<br />إذا كان الطبيب المعالج لك قد أخبرك بأنك لا تتحمل بعض أنواع السكريات، فاستشره قبل تناول هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>۳. كيفية تناول توريكوكس<br />تناول هذا الدَّواء دائمًا وفقًا لتعليمات الطبيب المعالج لك بالضبط. ويجب عليك استشارة الطبيب المعالج لك أو<br />الصيدلي الخاص بك إذا لم تكن متأكدًا من كيفية التناوُل.<br />لا تتناول أكثر من الجرعة الموصى بها لحالتك. سيحتاج الطبيب المعالج لك إلى فحص ضغط الدَّم لديك بشكل<br />لوقت أطول من &trade; منتظم. من المهم استخدام أدنى جُرعة تتحكَّم في الألم لديك، ويجب عدم استخدام توريكوكس<br />اللازم وذلك بسبب ازدياد نسبة خطر تعرضك للإصابة بنوبات قلبية وسكتات دماغية بعد العلاج لفترة طويلة،<br />خاصة العلاج بجرعات مرتفعة.<br />تتوفر تركيزات مختلفة لهذا المنتج الدوائي ويعتمد اختيار التركيز المستخدم على طبيعة حالتك، وسيصف<br />الطبيب المعالج لك تركيز الأقراص الملائم لحالتك.<br />الجرعة الموصى بها هي:<br />التهاب المفاصل<br />الجُرعة الموصى بها هي ۳۰ ملجم يوميًّا، وقد يزيدها الطبيب المعالج لك إلى ٦۰ ملجم كحد أقصى إذا تطلَّب<br />الأمر ذلك.<br />التهاب المفاصل الروماتويدي<br />الجُرعة الموصى بها هي ٦۰ ملجم يوميًّا، وقد يزيدها الطبيب المعالج لك إلى ۹۰ ملجم كحد أقصى إذا تطلَّب<br />الأمر ذلك.<br />التهاب الفقرات التيبسي<br />الجُرعة الموصى بها هي ٦۰ ملجم يوميًّا، وقد يرفعها الطبيب المعالج لك إلى ۹۰ ملجم كحد أقصى إذا تطلَّب<br />الأمر ذلك.<br />حالات الألم الحاد<br />يجب عدم استخدام إتوريكوكسيب إلا في فترات الألم الحاد.<br />النقرس<br />الجُرعة الموصى بها هي ۱۲۰ ملجم يوميًّا، ويجب عدم استخدامها إلا في حالات الألم الحاد وتصل فترة العلاج<br />إلى ۸ أيام بحد أقصى.<br />ألم ما بعد الخضوع لجراحة الأسنان<br />الجرعة الموصى بها هي ۹۰ ملجم مرة واحدة يوميًّا لفترة تصل إلى ۳ أيام بحد أقصى.<br />المرضى الذين يعانون من مشاكل في الكبد<br />&bull; يجب ألا تزيد عن ٦۰ ملجم يوميًّا، إذا كنت مصابًا بمرض طفيف الشدة في الكبد.<br />&bull; يجب ألا تزيد عن ۳۰ ملجم يوميًّا، إذا كنت مصابًا بمرض متوسط الشدة في الكبد.<br />الاستخدام للأطفال والمراهقين<br />على الأطفال والمراهقين الذين تقل أعمارهم عن ۱٦ عامًا. &trade; يحظر تناوُل توريكوكس<br />كبار السن<br />لا يلزم تعديل الجرعة للمرضى من كبار السن. مثله مثل الأدوية الأخرى، يجب توخي الحذر عند استخدامه<br />للمرضى من كبار السن.<br />طريقة التَّناول</p><p>ع &trade; مخصص للتناوُل عن طريق الفم. تناول الأقراص مرة واحدة يوميًّا. يمكن تناوُل توريكوكس &trade; توريكوكس<br />الطعام أو بدونه.<br />&trade; إذا تناولت جرعة زائدة من توريكوكس<br />،&trade; يجب ألا تتناول أبدًا عدد أقراص أكثر من الذي وصفه الطبيب لك. إذا تناولت عدد كبير من أقراص توريكوكس<br />يجب أن تحصل على الرعاية الطبية على الفور.<br />&trade; إذا أغفلت تناول توريكوكس<br />طبقًا لتعليمات الطبيب المعالج لك. إذا أغفلت تناول جرعة، استمر في اتباع &trade; من المهم أن تتناول توريكوكس<br />مواعيد تناول الدواء المعتادة في اليوم التالي. لا تتناول جرعة مضاعفة لتعويض الجرعة التي أغفلتها.<br />إذا كانت لديك أية أسئلة إضافية حول استخدام هذا الدواء، فاستشر الطبيب المعالج لك أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>٤. الآثار الجانبية المحتملة<br />مثله مثل كافة الأدوية، قد يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم حدوثها للجميع.<br />واستشر الطبيب المعالج لك فورًا إذا أصبت بأي من هذه الأعراض &trade; يجب أن تتوقف عن تناول توريكوكس<br />:( قسم ۲ ،&trade; (انظر ما تحتاج إلى معرفته قبل تناوُل توريكوكس<br />&bull; ضيق تنفس أو آلام في الصدر أو تورم الكاحل أو تدهور حالة تورم الكاحل.<br />&bull; اصفرار الجلد والعينين (يرقان) - تدل هذه الأعراض على وجود اضطرابات في الكبد.<br />&bull; ألم شديد أو مستمر في المعدة أو تحول لون البراز إلى اللون الأسود.<br />&bull; تفاعل حساسية - والذي قد يتضمن حدوث اضطرابات في الجلد مثل التقرحات أو ظهور بثور أو تورم الوجه أو<br />الشفتين أو اللسان أو الحلق والذي قد يؤدي إلى صعوبة في التنفس.<br />يعرف معدل تكرار الآثار الجانبية المحتملة المدرجة أدناه باستخدام الاصطلاحات التالية: شائعة جدًّا (تُؤثر على<br />أكثر مريض من بين كل ۱۰ مرضى)<br />شائعة (تؤثر على مريض إلى ۱۰ مرضى من بين كل ۱۰۰ مريض)، غير شائعة (تُؤثر على مريض إلى ۱۰<br />مرضى من بين كل ۱٫۰۰۰ مرضى)<br />نادرة (تؤثر على مريض إلى ۱۰ مرضى من بين كل ۱۰٫۰۰۰ مريض) نادرة جدًّا (تؤثر على أقل من مريض<br />من بين كل ۱۰,۰۰۰ مريض)<br />:&trade; من الممكن حدوث الآثار الجانبية التالية خلال فترة العلاج بتوريكوكس<br />شائعة جداًّ:<br />&bull; ألم بالمعدة<br />شائعة:<br />&bull; جفاف تجويف السن (التهاب وألم بعد خلع سن).<br />&bull; تورم الساقين و/أو القدمين الناجم عن احتباس السوائل (وذمة).<br />&bull; دوخة، صداع.<br />&bull; خفقان (زيادة سرعة ضربات القلب أو عدم انتظامها)، عدم انتظام نظم القلب.<br />&bull; ارتفاع ضغط الدم.<br />&bull; أزيز بالصدر أو ضيق بالتنفس (تشنجات قصبية).<br />&bull; إمساك، ريح (غازات زائدة)، التهاب المعدة (التهاب بطانة المعدة)، حموضة، إسهال، عسر هضم/شعور بعد<br />راحة في المعدة، غثيان، إعياء (قيء)، التهاب المريء، قرح بالفم.<br />&bull; تغير في نتائج فحص الدم الخاصة بالكبد.<br />&bull; تكدُّم.<br />&bull; ضعف وإرهاق، أعراض تشبه الإنفلونزا.<br />غير شائعة:<br />&bull; التهاب الجهاز الهضمي (التهاب المسار الهضمي الذي يتضمن المعدة والأمعاء الدقيقة/إنفلونزا في المعدة)،<br />عدوى الجهاز التنفسي العلوي، عدوى المسالك البولية.<br />&bull; تغيرات في نتائج المختبر (انخفاض عدد خلايا الدم الحمراء، انخفاض عدد خلايا الدم البيضاء، انخفاض عدد<br />الصفائح الدموية).<br />&bull; فرط الحساسية (تفاعل حساسية يتضمن أرتكاريا والذي قد تصل خطورته إلى حد الحاجة إلى عناية طبية فورية)<br />&bull; زيادة الشهية أو انخفاضها، زيادة الوزن.<br />&bull; قلق، اكتئاب، انخفاض نسبة الانتباه، رؤية أشياء غير موجودة أو الشعور بها أو سماعها (هلاوس).<br />&bull; تغير حاسة التذوق، عدم القدرة على النوم، تخدر وتنميل، نعاس.<br />&bull; عدم وضوح الرؤية وتهيج بالعينين واحمرارهما.<br />&bull; طنين في الأذنين، دوار (شعور بالدوران أثناء التوقف).<br />&bull; اضطراب نظم القلب (رجفان أذيني)، زيادة معدل ضربات القلب، فشل القلب، شعور بضيق أو ضغط أو ثقل في<br />الصدر (ذبحة صدرية)، نوبة قلبية.<br />&bull; احمرار، سكتة دماغية، سكتة دماغية صغرى (نوبة إقفارية مؤقتة)، ارتفاع شديد في ضغط الدم، التهاب الأوعية<br />الدموية.<br />&bull; سعال، ضيق تنفس، نزيف الأنف.<br />&bull; انتفاخ المعدة أو الأمعاء، اضطرابات في حركة الأمعاء، جفاف الفم، تقرح المعدة، التهاب بطانة المعدة الذي قد<br />يصبح خطيرًا ويؤدي لنزيف، متلازمة القولون العصبي، التهاب البنكرياس.<br />&bull; تورم الوجه، طفح جلدي أو حكة الجلد أو احمرار بالجلد.<br />&bull; تقلص/تشنج العضلات، ألم/تصلب العضلات<br />&bull; ارتفاع مستوى البوتاسيوم في الدم، تغير نتائج فحوصات الدم أو البول الخاصة بالكلى، اضطرابات خطيرة في<br />الكلى.<br />&bull; ألم بالصدر.<br />نادرة:<br />&bull; وذمة وعائية (تفاعل حساسية يشمل تورم الوجه و/أو الشفاه و/أو اللسان و/أو الحلق، الذي قد يؤدي إلى صعوبة<br />في التنفس أو البلع، وقد يصبح خطيرًا لدرجة أن يتطلب عناية طبية فورية)/ تفاعلات فرط حساسية/شبيهة بفرط<br />الحساسية وتتضمن صدمة (تفاعل حساسية خطير يتطلب عناية طبية فورية)<br />&bull; ارتباك، تململ<br />&bull; اضطرابات الكبد (التهاب الكبد).<br />&bull; انخفاض مستوى الصوديوم في الدم.<br />&bull; فشل كبدي، اصفرار الجلد و/أو العينين (يرقان).<br />&bull; تفاعلات جلدية شديدة.<br />الإبلاغ عن الآثار الجانبية<br />إذا أصبت بأيَّة آثار جانبية، فتحدَّث إلى الطبيب المعالج لك أو الصيدلي الخاص بك. بما في ذلك أية آثار جانبية<br />مُحتمَلة، غير المُدرجة في هذه النَّشرة. من خلال إبلاغك عن الآثار الجانبية، يمكنك المُساعدة في توفير معلومات<br />إضافية حول أمان استخدام هذا الدَّواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٥. كيفية تخزين توريكوكس<br />يُحفظ بعيدًا عن متناول و مرأى الأطفال.<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية.<br />لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة الكرتونيَّة.<br />لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك<br />عن كيفية التَّخلص من الأدوية التي لم تعد تستخدمها. سوف تُساعد هذه الإجراءات في الحفاظ على البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٦. معلومات إضافية<br />&trade; على ماذا يحتوي توريكوكس<br />۱۲۰ ملجم من إتوريكوكسيب. /۹۰ / يحتوي كل قرص مغلف على ٦۰<br />المكونات الأخرى:<br />يحتوي على<br />فوسفات ثنائي الكالسيوم اللا مائي، سليلوز دقيق التَبلّور، بوفيدون، كروسكارميلوز الصوديوم، ستيرات<br />الماغنسيوم.<br />الغلاف الخارجي:<br />۳۲ (تحتوي على هيبروميلوز، لاكتوز أحادي الهيدرات، ثاني K أقراص ٦۰ ملجم: أوبادري ۲ أخضر ۲۱۰۰۱۸<br />رقم ۲/ انديجو كارمين &quot;Fd&amp;C&quot; أكسيد التيتانيوم، ثُلاثي الأَستين، أكسيد الحديد الأصفر، صبغة زرقاء فاتحة<br />ألومنيوم ليك)<br />۳۲ (يحتوي على هيبروميلوز، لاكتوز أحادي الهيدرات، ثاني K أقراص ۹۰ ملجم: أوبادري ۲ أبيض - ۲۸۰۰۰۰<br />أكسيد التيتانيوم، ثلاثي الأَستين)<br />۳۲ (تحتوي على هيبروميلوز، لاكتوز أحادي الهيدرات، K أقراص ۱۲۰ ملجم: أوبادري ۲ أخضر ٥۱۰۰۰۳<br />رقم ۲/انديجو كارمين &quot;Fd&amp;C&quot; ثاني أكسيد التيتانيوم، ثُلاثي الأَستين، أكسيد الحديد الأصفر، صبغة زرقاء فاتحة<br />ألومنيوم ليك).</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><br />وما هي محتويات العبوة؟ ؟&trade; ما هو شكل توريكوكس<br />٦۰ ملجم: أقراص مغلفة محدبة الوجهين مستديرة الشكل لونها أخضر داكن، محفور على أحد &trade; توريكوكس<br />.&quot;AK&quot; وعلى الجانب الآخر &quot;JP&quot; جانبيها<br />۹۰ ملجم: أقراص مغلفة محدبة الوجهين مستديرة الشكل لونها أبيض، محفور على أحد جانبيها &trade; توريكوكس<br />.&quot;AL&quot; وعلى الجانب الآخر &quot;JP&quot;<br />۱۲۰ ملجم: أقراص مغلفة محدبة الوجهين مستديرة الشكل لونها أخضر باهت، محفور على أحد &trade; توريكوكس<br />.&quot; وعلى الجانب الآخر &quot; ۱٦۷ &quot;JP&quot; جانبيها<br />٦۰ ملجم في عبوة من ۳ أشرطة يحتوي كل منها على ۳۰ أقراص. &trade; يتوفر توريكوكس<br />۹۰ ملجم في عبوة من ۳ أشرطة يحتوي كل منها على ۳۰ أقراص. &trade; يتوفر توريكوكس<br />۱۲۰ ملجم في عبوة من شريط واحد يحتوي على ۱۰ أقراص. &trade; يتوفر توريكوكس</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><img src="data:image/png;base64,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" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Toricox 120 mg Film Coated Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated tablet contains:
Etoricoxib 120 mg
For a full list of excipients see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated Tablets
Pale Green colored, round, biconvex, film coated tablets, debossed with 'JP' on one side and '128' on
other side.
Commercial tablets shall have the following description
Pale green colored, round, biconvex, film coated tablets, debossed with ‘JP’ on one side and ‘167’ on
other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:-4.5pt; text-align:justify"><strong><em><u>Adults</u></em></strong><strong><em> </em></strong></p><p style="margin-left:-4.5pt; text-align:justify">ETORICOXIB is indicated in adults and adolescents 16 years of age and older for the symptomatic relief of osteoarthritis (OA), rheumatoid arthritis (RA), ankylosing spondylitis, and the pain and signs of inflammation associated with acute gouty arthritis.</p><p style="margin-left:-4.5pt; text-align:justify">ETORICOXIB is indicated in adults and adolescents 16 years of age and older for the short-term treatment of moderate pain associated with dental surgery.</p><p style="margin-left:-4.5pt; text-align:justify">The decision to prescribe a selective COX-2 inhibitor should be based on an assessment of the individual patient&#39;s overall risks (see sections 4.3, 4.4)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Posology</p><p style="text-align:justify">As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Osteoarthritis</p><p style="text-align:justify">The recommended dose is 30 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 60 mg once daily may increase efficacy. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Rheumatoid arthritis</p><p style="text-align:justify">The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Ankylosing spondylitis</p><p style="text-align:justify">The recommended dose is 60 mg once daily. In some patients with insufficient relief from symptoms, an increased dose of 90 mg once daily may increase efficacy. Once the patient is clinically stabilised, down-titration to a 60 mg once daily dose may be appropriate. In the absence of an increase in therapeutic benefit, other therapeutic options should be considered.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Acute pain conditions</p><p style="text-align:justify">For acute pain conditions, etoricoxib should be used only for the acute symptomatic period.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Acute gouty arthritis</p><p style="text-align:justify">The recommended dose is 120 mg once daily. In clinical trials for acute gouty arthritis, etoricoxib was given for 8 days.</p><p style="text-align:justify">Postoperative dental surgery pain</p><p style="text-align:justify">The recommended dose is 90 mg once daily, limited to a maximum of 3 days. Some patients may require other postoperative analgesia in addition to ETORICOXIB during the three day treatment period.</p><p style="text-align:justify">Doses greater than those recommended for each indication have either not demonstrated additional efficacy or have not been studied. Therefore:</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The dose for OA should not exceed 60 mg daily.</p><p style="text-align:justify">The dose for RA and ankylosing spondylitis should not exceed 90 mg daily.</p><p style="text-align:justify">The dose for acute gout should not exceed 120 mg daily, limited to a maximum of 8 days treatment.</p><p style="text-align:justify">The dose for postoperative acute dental surgery pain should not exceed 90 mg daily, limited to a maximum of 3 days.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Special populations</p><p style="text-align:justify">Elderly patients</p><p style="text-align:justify">No dosage adjustment is necessary for elderly patients. As with other drugs, caution should be exercised in elderly patients.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Patients with hepatic impairment</p><p style="text-align:justify">Regardless of indication, in patients with mild hepatic dysfunction (Child-Pugh score 5-6) a dose of 60 mg once daily should not be exceeded. In patients with moderate hepatic dysfunction (Child-Pugh score 7-9), regardless of indication, the dose of 30 mg once daily should not be exceeded.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Clinical experience is limited particularly in patients with moderate hepatic dysfunction and caution is advised. There is no clinical experience in patients with severe hepatic dysfunction (Child-Pugh score &ge;10); therefore, its use is contra-indicated in these patients.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Patients with renal impairment</p><p style="text-align:justify">No dosage adjustment is necessary for patients with creatinine clearance &ge;30 ml/min. The use of etoricoxib in patients with creatinine clearance &lt;30 ml/min is contra-indicated.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Paediatric population</p><p style="text-align:justify">Etoricoxib is contra-indicated in children and adolescents under 16 years of age.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Method of administration</p><p style="text-align:justify">ETORICOXIB is administered orally and may be taken with or without food. The onset of the effect of the medicinal product may be faster when ETORICOXIB is administered without food. This should be considered when rapid symptomatic relief is needed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Active peptic ulceration or active gastro-intestinal (GI) bleeding.
• Patients who, after taking acetylsalicylic acid or NSAIDs including COX-2 (cyclooxygenase-2) inhibitors, experience bronchospasm, acute rhinitis, nasal polyps, angioneurotic oedema, urticaria, or allergic-type reactions.
• Pregnancy and lactation.
• Severe hepatic dysfunction (serum albumin <25 g/l or Child-Pugh score ≥10).
• Estimated renal creatinine clearance <30 ml/min.
• Children and adolescents under 16 years of age.
• Inflammatory bowel disease.
• Congestive heart failure (NYHA II-IV).
• Patients with hypertension whose blood pressure is persistently elevated above 140/90 mmHg and has not been adequately controlled.
• Established ischaemic heart disease, peripheral arterial disease, and/or cerebrovascular disease.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Gastrointestinal effects</em></p><p style="text-align:justify">Upper gastrointestinal complications [perforations, ulcers or bleedings (PUBs)], some of them resulting in fatal outcome, have occurred in patients treated with etoricoxib.</p><p style="text-align:justify">Caution is advised with treatment of patients most at risk of developing a gastrointestinal complication with NSAIDs; the elderly, patients using any other NSAID or acetylsalicylic acid concomitantly or patients with a prior history of gastrointestinal disease, such as ulceration and GI bleeding.</p><p style="text-align:justify">There is a further increase in the risk of gastrointestinal adverse effects (gastrointestinal ulceration or other gastrointestinal complications) when etoricoxib is taken concomitantly with acetylsalicylic acid (even at low doses). A significant difference in GI safety between selective COX-2 inhibitors + acetylsalicylic acid&nbsp;<em>vs</em>. NSAIDs + acetylsalicylic acid has not been demonstrated in long-term clinical trials.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Cardiovascular effects</em></p><p style="text-align:justify">Clinical trials suggest that the selective COX-2 inhibitor class of drugs may be associated with a risk of thrombotic events (especially myocardial infarction (MI) and stroke), relative to placebo and some NSAIDs. As the cardiovascular risks of etoricoxib may increase with dose and duration of exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need for symptomatic relief and response to therapy should be re-evaluated periodically, especially in patients with osteoarthritis.</p><p style="text-align:justify">Patients with significant risk factors for cardiovascular events (e.g. hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with etoricoxib after careful consideration.</p><p style="text-align:justify">COX-2 selective inhibitors are not a substitute for acetylsalicylic acid for prophylaxis of cardiovascular thrombo-embolic diseases because of their lack of antiplatelet effect. Therefore antiplatelet therapies should not be discontinued.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Renal effects</em></p><p style="text-align:justify">Renal prostaglandins may play a compensatory role in the maintenance of renal perfusion. Therefore, under conditions of compromised renal perfusion, administration of etoricoxib may cause a reduction in prostaglandin formation and, secondarily, in renal blood flow, and thereby impair renal function. Patients at greatest risk of this response are those with pre-existing significantly impaired renal function, uncompensated heart failure, or cirrhosis. Monitoring of renal function in such patients should be considered.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Fluid retention, oedema and hypertension</em></p><p style="text-align:justify">As with other medicinal products known to inhibit prostaglandin synthesis, fluid retention, oedema and hypertension have been observed in patients taking etoricoxib. All Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including etoricoxib, can be associated with new onset or recurrent congestive heart failure. For information regarding a dose related response for etoricoxib. Caution should be exercised in patients with a history of cardiac failure, left ventricular dysfunction, or hypertension and in patients with pre-existing oedema from any other reason. If there is clinical evidence of deterioration in the condition of these patients, appropriate measures including discontinuation of etoricoxib should be taken.</p><p style="text-align:justify">Etoricoxib may be associated with more frequent and severe hypertension than some other NSAIDs and selective COX-2 inhibitors, particularly at high doses. Therefore, hypertension should be controlled before treatment with etoricoxib and special attention should be paid to blood pressure monitoring during treatment with etoricoxib. Blood pressure should be monitored within two weeks after initiation of treatment and periodically thereafter. If blood pressure rises significantly, alternative treatment should be considered.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Hepatic effects</em></p><p style="text-align:justify">Elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) (approximately three or more times the upper limit of normal) have been reported in approximately 1% of patients in clinical trials treated for up to one year with etoricoxib 30, 60 and 90 mg daily.</p><p style="text-align:justify">Any patients with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver function test has occurred, should be monitored. If signs of hepatic insufficiency occur, or if persistently abnormal liver function tests (three times the upper limit of normal) are detected, etoricoxib should be discontinued.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>General</em></p><p style="text-align:justify">If during treatment, patients deteriorate in any of the organ system functions described above, appropriate measures should be taken and discontinuation of etoricoxib therapy should be considered. Medically appropriate supervision should be maintained when using etoricoxib in the elderly and in patients with renal, hepatic, or cardiac dysfunction.</p><p style="text-align:justify">Caution should be used when initiating treatment with etoricoxib in patients with dehydration. It is advisable to rehydrate patients prior to starting therapy with etoricoxib.</p><p style="text-align:justify">Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs and some selective COX-2 inhibitors during post-marketing surveillance. Patients appear to be at highest risk for these reactions early in the course of therapy with the onset of the reaction occurring in the majority of cases within the first month of treatment. Serious hypersensitivity reactions (such as anaphylaxis and angioedema) have been reported in patients receiving etoricoxib. Some selective COX-2 inhibitors have been associated with an increased risk of skin reactions in patients with a history of any drug allergy. Etoricoxib should be discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.</p><p style="text-align:justify">Etoricoxib may mask fever and other signs of inflammation.</p><p style="text-align:justify">Caution should be exercised when co-administering etoricoxib with warfarin or other oral anticoagulants.</p><p style="text-align:justify">The use of etoricoxib, as with any medicinal product known to inhibit cyclooxygenase / prostaglandin synthesis, is not recommended in women attempting to conceive.</p><p style="text-align:justify">ETORICOXIB tablets contain lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Pharmacodynamic interactions</em></p><p style="text-align:justify"><em>Oral anticoagulants:</em>&nbsp;In subjects stabilised on chronic warfarin therapy, the administration of etoricoxib 120 mg daily was associated with an approximate 13% increase in prothrombin time International Normalised Ratio (INR). Therefore, patients receiving oral anticoagulants should be closely monitored for their prothrombin time INR, particularly in the first few days when therapy with etoricoxib is initiated or the dose of etoricoxib is changed.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Diuretics, ACE inhibitors and Angiotensin II Antagonists:</em>&nbsp;NSAIDs may reduce the effect of diuretics and other antihypertensive drugs. In some patients with compromised renal function (e.g. dehydrated patients or elderly patients with compromised renal function) the co-administration of an ACE inhibitor or Angiotensin II antagonist and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. These interactions should be considered in patients taking etoricoxib concomitantly with ACE inhibitors or angiotensin II antagonists. Therefore, the combination should be administered with caution, especially in the elderly. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy, and periodically thereafter.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Acetylsalicylic Acid:</em>&nbsp;In a study in healthy subjects, at steady state, etoricoxib 120 mg once daily had no effect on the anti-platelet activity of acetylsalicylic acid (81 mg once daily). Etoricoxib can be used concomitantly with acetylsalicylic acid at doses used for cardiovascular prophylaxis (low-dose acetylsalicylic acid). However, concomitant administration of low-dose acetylsalicylic acid with etoricoxib may result in an increased rate of GI ulceration or other complications compared to use of etoricoxib alone. Concomitant administration of etoricoxib with doses of acetylsalicylic acid above those for cardiovascular prophylaxis or with other NSAIDs is not recommended.</p><p style="text-align:justify"><em>Cyclosporin and tacrolimus:</em>&nbsp;Although this interaction has not been studied with etoricoxib, coadministration of cyclosporin or tacrolimus with any NSAID may increase the nephrotoxic effect of cyclosporin or tacrolimus. Renal function should be monitored when etoricoxib and either of these drugs is used in combination.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Pharmacokinetic interactions</em></p><p style="text-align:justify"><em>The effect of etoricoxib on the pharmacokinetics of other drugs</em></p><p style="text-align:justify"><em>Lithium:</em>&nbsp;NSAIDs decrease lithium renal excretion and therefore increase lithium plasma levels. If necessary, monitor blood lithium closely and adjust the lithium dosage while the combination is being taken and when the NSAID is withdrawn.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Methotrexate:</em>&nbsp;Two studies investigated the effects of etoricoxib 60, 90 or 120 mg administered once daily for seven days in patients receiving once-weekly methotrexate doses of 7.5 to 20 mg for rheumatoid arthritis. Etoricoxib at 60 and 90 mg had no effect on methotrexate plasma concentrations or renal clearance. In one study, etoricoxib 120 mg had no effect, but in the other study, etoricoxib 120 mg increased methotrexate plasma concentrations by 28% and reduced renal clearance of methotrexate by 13%. Adequate monitoring for methotrexate-related toxicity is recommended when etoricoxib and methotrexate are administered concomitantly.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Oral contraceptives:</em>&nbsp;Etoricoxib 60 mg given concomitantly with an oral contraceptive containing 35 micrograms ethinyl estradiol (EE) and 0.5 to 1 mg norethindrone for 21 days increased the steady state AUC<sub>0-24hr</sub>&nbsp;of EE by 37%. Etoricoxib 120 mg given with the same oral contraceptive concomitantly or separated by 12 hours, increased the steady state AUC<sub>0-24hr</sub>&nbsp;of EE by 50 to 60%. This increase in EE concentration should be considered when selecting an oral contraceptive for use with etoricoxib. An increase in EE exposure can increase the incidence of adverse events associated with oral contraceptives (e.g., venous thrombo-embolic events in women at risk).</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Hormone Replacement Therapy (HRT):</em>&nbsp;Administration of etoricoxib 120 mg with hormone replacement therapy consisting of conjugated estrogens (0.625 mg PREMARIN<sup>TM</sup>) for 28 days, increased the mean steady state AUC<sub>0-24hr</sub>&nbsp;of unconjugated estrone (41%), equilin (76%), and 17-&beta;-estradiol (22%). The effect of the recommended chronic doses of etoricoxib (30, 60, and 90 mg) has not been studied. The effects of etoricoxib 120 mg on the exposure (AUC<sub>0-24hr</sub>) to these estrogenic components of PREMARIN were less than half of those observed when PREMARIN was administered alone and the dose was increased from 0.625 to 1.25 mg. The clinical significance of these increases is unknown, and higher doses of PREMARIN were not studied in combination with etoricoxib. These increases in estrogenic concentration should be taken into consideration when selecting post-menopausal hormone therapy for use with etoricoxib because the increase in oestrogen exposure might increase the risk of adverse events associated with HRT.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Prednisone/prednisolone:&nbsp;</em>In drug-interaction studies, etoricoxib did not have clinically important effects on the pharmacokinetics of prednisone/prednisolone.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Digoxin:</em>&nbsp;Etoricoxib 120 mg administered once daily for 10 days to healthy volunteers did not alter the steady-state plasma AUC<sub>0-24hr</sub>&nbsp;or renal elimination of digoxin. There was an increase in digoxin C<sub>max</sub>&nbsp;(approximately 33%). This increase is not generally important for most patients. However, patients at high risk of digoxin toxicity should be monitored for this when etoricoxib and digoxin are administered concomitantly.</p><p style="text-align:justify"><em>Effect of etoricoxib on drugs metabolised by sulfotransferases</em></p><p style="text-align:justify">Etoricoxib is an inhibitor of human sulfotransferase activity, particularly SULT1E1, and has been shown to increase the serum concentrations of ethinyl estradiol. While knowledge about effects of multiple sulfotransferases is presently limited and the clinical consequences for many drugs are still being examined, it may be prudent to exercise care when administering etoricoxib concurrently with other drugs primarily metabolised by human sulfotransferases (e.g., oral salbutamol and minoxidil).</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Effect of etoricoxib on drugs metabolised by CYP isoenzymes</em></p><p style="text-align:justify">Based on&nbsp;<em>in vitro</em>&nbsp;studies, etoricoxib is not expected to inhibit cytochromes P450 (CYP) 1A2, 2C9, 2C19, 2D6, 2E1 or 3A4. In a study in healthy subjects, daily administration of etoricoxib 120 mg did not alter hepatic CYP3A4 activity as assessed by the erythromycin breath test.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Effects of other drugs on the pharmacokinetics of etoricoxib</em></p><p style="text-align:justify">The main pathway of etoricoxib metabolism is dependent on CYP enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib&nbsp;<em>in vivo</em>.&nbsp;<em>In vitro</em>&nbsp;studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their quantitative roles have not been studied<em>&nbsp;in vivo</em>.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Ketoconazole:</em>&nbsp;Ketoconazole, a potent inhibitor of CYP3A4, dosed at 400 mg once a day for 11 days to healthy volunteers, did not have any clinically important effect on the single-dose pharmacokinetics of 60 mg etoricoxib (43% increase in AUC).</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Voriconazole and Miconazole</em>: Co-administration of either oral voriconazole or topical miconazole oral gel, strong CYP3A4 inhibitors, with etoricoxib caused a slight increase in exposure to etoricoxib, but is not considered to be clinically meaningful based on published data.</p><p style="text-align:justify"><em>Rifampicin:</em>&nbsp;Co-administration of etoricoxib with rifampicin, a potent inducer of CYP enzymes, produced a 65% decrease in etoricoxib plasma concentrations. This interaction may result in recurrence of symptoms when etoricoxib is co-administered with rifampicin. While this information may suggest an increase in dose, doses of etoricoxib greater than those listed for each indication have not been studied in combination with rifampicin and are therefore not recommended (see section 4.2).</p><p style="text-align:justify"><em>Antacids:</em>&nbsp;Antacids do not affect the pharmacokinetics of etoricoxib to a clinically relevant extent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>No clinical data on exposed pregnancies are available for etoricoxib. Studies in animals have shown reproductive toxicity (see section 5.3). The potential for human risk in pregnancy is unknown. Etoricoxib, as with other medicinal products inhibiting prostaglandin synthesis, may cause uterine inertia and premature closure of the ductus arteriosus during the last trimester. Etoricoxib is contraindicated in pregnancy (see section 4.3). If a woman becomes pregnant during treatment, etoricoxib must be discontinued.</p><p>&nbsp;</p><p>Breastfeeding</p><p>It is not known whether etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk of lactating rats. Women who use etoricoxib must not breast feed (see sections 4.3 and 5.3).</p><p>&nbsp;</p><p>Fertility</p><p style="text-align:justify">The use of etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Patients who experience dizziness, vertigo or somnolence while taking etoricoxib should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Summary of the safety profile</em></p><p style="text-align:justify">In clinical trials, etoricoxib was evaluated for safety in 9,295 individuals, including 6,757 patients with OA, RA, chronic low back pain or ankylosing spondylitis (approximately 600 patients with OA or RA were treated for one year or longer).</p><p style="text-align:justify">In clinical studies, the undesirable effects profile was similar in patients with OA or RA treated with etoricoxib for one year or longer.</p><p style="text-align:justify">In a clinical study for acute gouty arthritis, patients were treated with etoricoxib 120 mg once daily for eight days. The adverse experience profile in this study was generally similar to that reported in the combined OA, RA, and chronic low back pain studies.</p><p style="text-align:justify">In a cardiovascular safety outcomes programme of pooled data from three active comparator controlled trials, 17, 412 patients with OA or RA were treated with etoricoxib (60 mg or 90 mg) for a mean duration of approximately 18 months. The safety data and details from this programme are presented in section 5.1.</p><p style="text-align:justify">In clinical studies for acute postoperative dental pain following surgery including 614 patients treated with etoricoxib (90 mg or 120 mg), the adverse experience profile in these studies was generally similar to that reported in the combined OA, RA, and chronic low back pain studies.</p><p style="text-align:justify"><em>Tabulated list of adverse reactions</em></p><p style="text-align:justify">The following undesirable effects were reported at an incidence greater than placebo in clinical trials in patients with OA, RA, chronic low back pain or ankylosing spondylitis treated with etoricoxib 30 mg, 60 mg or 90 mg up to the recommended dose for up to 12 weeks; in the MEDAL Programme studies for up to 3&frac12; years; in short term acute pain studies for up to 7 days; or in post-marketing experience (see Table 1):</p><p style="text-align:justify"><strong>Table 1:</strong></p><table cellspacing="0" cellpadding="0" border="1" style="width:108.22%"><tbody><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong>System Organ Class</strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify"><strong>Adverse Reactions</strong></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify"><strong>Frequency Category*</strong></p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Infections and infestations</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">alveolar osteitis</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">gastroenteritis, upper respiratory infection, urinary tract infection</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Blood and lymphatic system disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">anaemia (primarily associated with gastrointestinal bleeding), leukopenia, thrombocytopenia</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Immune system disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">hypersensitivity<sup>&Dagger; &nbsp; &szlig;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">angioedema/anaphylactic /anaphylactoid reactions including shock<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Rare</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Metabolism and nutrition disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">oedema/fluid retention</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">appetite increase or decrease, weight gain</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Psychiatric disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">anxiety, depression, mental acuity decreased, hallucinations<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">confusion<sup>&Dagger;</sup><em>,&nbsp;</em>restlessness<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Rare</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Nervous system disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">dizziness, headache</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">dysgeusia, insomnia, paresthaesia/hypaesthesia, somnolence</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Eye disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">blurred vision, conjunctivitis</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Ear and labyrinth disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">tinnitus, vertigo</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Cardiac disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">palpitations, arrhythmia<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">atrial fibrillation, tachycardia<sup>&Dagger;</sup><em>,&nbsp;</em>congestive heart failure, non-specific ECG changes, angina pectoris<sup>&Dagger;</sup>, myocardial infarction<sup>&sect;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Vascular disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">hypertension</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">flushing, cerebrovascular accident<sup>&sect;</sup>, transient ischaemic attack, hypertensive crisis<sup>&Dagger;</sup><em>,&nbsp;</em>vasculitis<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Respiratory, thoracic and mediastinal disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">bronchospasm<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">cough, dyspnoea, epistaxis</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Gastrointestinal disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">abdominal pain</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Very common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">Constipation, flatulence, gastritis, heartburn/acid reflux, diarrhea, dyspepsia/epigastric discomfort, nausea, vomiting, oesophagitis, oral ulcer</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">abdominal distention, bowel movement pattern change, dry mouth, gastroduodenal ulcer, peptic ulcers including gastrointestinal perforation and bleeding, irritable bowel syndrome, pancreatitis<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Hepatobiliary disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">ALT increased, AST increased</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">hepatitis<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Rare</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">hepatic failure<sup>&Dagger;</sup>, jaundice<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Rare<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Skin and subcutaneous tissue disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">ecchymosis</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">facial oedema, pruritus, rash, erythema<sup>&Dagger;</sup>, urticaria<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">Stevens-Johnson syndrome<sup>&Dagger;</sup>, toxic epidermal necrolysis<sup>&Dagger;</sup>, fixed drug eruption<sup>&Dagger;</sup></p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Rare<sup>&dagger;</sup></p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Musculoskeletal and </em></strong></p><p style="text-align:justify"><strong><em>connective tissue disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">muscular cramp/spasm, musculoskeletal pain/stiffness</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Renal and urinary disorders</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">proteinuria, serum creatinine increased, renal failure/renal insufficiency<sup>&Dagger;</sup>(see section 4.4)</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="height:58.75pt; vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>General disorders and </em></strong></p><p style="text-align:justify"><strong><em>administration site </em></strong></p><p style="text-align:justify"><strong><em>conditions</em></strong></p></td><td style="height:58.75pt; vertical-align:top; width:52.02%"><p style="text-align:justify">asthenia/fatigue, flu-like disease</p></td><td style="height:58.75pt; vertical-align:top; width:20.18%"><p style="text-align:justify">Common</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">chest pain</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%"><p style="text-align:justify"><strong><em>Investigations</em></strong></p></td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">blood urea nitrogen increased, creatine phosphokinase increased, hyperkalaemia, uric acid increased</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Uncommon</p></td></tr><tr><td style="vertical-align:top; width:27.8%">&nbsp;</td><td style="vertical-align:top; width:52.02%"><p style="text-align:justify">blood sodium decreased</p></td><td style="vertical-align:top; width:20.18%"><p style="text-align:justify">Rare</p></td></tr><tr><td colspan="3" style="vertical-align:top; width:100.0%"><p>*Frequency Category: Defined for each Adverse Experience Term by the incidence reported in the clinical trials data base: Very Common (&ge;1/10), Common (&ge;1/100 to &lt;1/10), Uncommon (&ge;1/1000 to &lt;1/100), Rare (&ge;1/10,000 to &lt;1/1000), Very Rare (&lt;1/10,000).</p><p><sup>&Dagger;</sup>&nbsp;This adverse reaction was identified through post-marketing surveillance. Its reported frequency has been estimated based upon the highest frequency observed across clinical trial data pooled by indication and approved dose.</p><p><sup>&dagger;</sup>The frequency category of &ldquo;Rare&rdquo; was defined per the Summary of Product Characteristics (SmPC) guidance (rev. 2, Sept 2009) on the basis of an estimated upper bound of the 95% confidence interval for 0 events given the number of subjects treated with ETORICOXIB in the analysis of the Phase III data pooled by dose and indication (n=15,470).</p><p><sup>&szlig;&nbsp;</sup>Hypersensitivity includes the terms &quot;allergy&quot;, &quot;drug allergy&quot;, &quot;drug hypersensitivity&quot;, &quot;hypersensitivity&quot;, &quot;hypersensitivity NOS&quot;, &quot;hypersensitivity reaction&quot; and &quot;nonspecific allergy&quot;.</p><p><sup>&sect;</sup>Based on analyses of long-term placebo and active controlled clinical trials, selective COX-2 inhibitors have been associated with an increased risk of serious thrombotic arterial events, including myocardial infarction and stroke. The absolute risk increase for such events is unlikely to exceed 1% per year based on existing data (uncommon).</p></td></tr></tbody></table><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">The following serious undesirable effects have been reported in association with the use of NSAIDs and cannot be ruled out for etoricoxib: nephrotoxicity including interstitial nephritis and nephrotic syndrome.</p><p style="margin-right:-4.0pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-4.0pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-4.0pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-4.0pt; text-align:justify"><strong>&nbsp;</strong></p><p style="margin-right:-4.0pt; text-align:justify"><strong>To report any side effect(s):</strong></p><p style="margin-right:-4.0pt; text-align:justify"><strong>&bull; Saudi Arabia:</strong></p><p style="margin-right:-4.0pt; text-align:justify">The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p style="margin-right:-4.0pt; text-align:justify">Fax: +966-11-205-7662</p><p style="margin-right:-4.0pt; text-align:justify">Call NPC at +966-11-2038222,</p><p style="margin-right:-4.0pt; text-align:justify">Exts: 2317-2356-2353-2354-2334-2340.</p><p style="margin-right:-4.0pt; text-align:justify">Toll free phone: 8002490000</p><p style="margin-right:-4.0pt; text-align:justify">E-mail: npc.drug@sfda.gov.sa</p><p style="margin-right:-4.0pt; text-align:justify">Website: <u>www.sfda.gov.sa/npc</u></p><p style="margin-left:-5.4pt; margin-right:-4.0pt; text-align:justify">&nbsp;</p><p style="margin-left:-5.4pt; margin-right:-4.0pt; text-align:justify">&nbsp; <strong>&bull; Other GCC States:</strong></p><p style="margin-left:-5.4pt; margin-right:-4.0pt; text-align:justify">&minus; Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">In clinical studies, administration of single doses of etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity. There have been reports of acute overdosage with etoricoxib, although adverse experiences were not reported in the majority of cases. The most frequently observed adverse experiences were consistent with the safety profile for etoricoxib (e.g. gastrointestinal events, cardiorenal events).</p><p style="text-align:justify">In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the GI tract, employ clinical monitoring, and institute supportive therapy, if required.</p><p style="text-align:justify">Etoricoxib is not dialysable by haemodialysis; it is not known whether etoricoxib is dialysable by peritoneal dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids, coxibs,&nbsp;</em></p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify">ATC code: M01 AH05</p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify"><u>Mechanism of Action</u></p><p style="text-align:justify">Etoricoxib is an oral, selective cyclo-oxygenase-2 (COX-2) inhibitor within the clinical dose range.</p><p style="text-align:justify">Across clinical pharmacology studies, ETORICOXIB produced dose-dependent inhibition of COX-2 without inhibition of COX-1 at doses up to 150 mg daily. Etoricoxib did not inhibit gastric prostaglandin synthesis and had no effect on platelet function.</p><p style="text-align:justify">Cyclooxygenase is responsible for generation of prostaglandins. Two isoforms, COX-1 and COX-2, have been identified. COX-2 is the isoform of the enzyme that has been shown to be induced by pro-inflammatory stimuli and has been postulated to be primarily responsible for the synthesis of prostanoid mediators of pain, inflammation, and fever. COX-2 is also involved in ovulation, implantation and closure of the ductus arteriosus, regulation of renal function, and central nervous system functions (fever induction, pain perception and cognitive function). It may also play a role in ulcer healing. COX-2 has been identified in tissue around gastric ulcers in man but its relevance to ulcer healing has not been established.</p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify"><u>Clinical efficacy and safety</u></p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify"><u>Efficacy</u></p><p style="text-align:justify">In patients with osteoarthritis (OA), etoricoxib 60 mg once daily provided significant improvements in pain and patient assessments of disease status. These beneficial effects were observed as early as the second day of therapy and maintained for up to 52 weeks. Studies with etoricoxib 30 mg once daily demonstrated efficacy superior to placebo over a 12 week treatment period (using similar assessments as the above studies). In a dose ranging study, etoricoxib 60 mg demonstrated significantly greater improvement than 30 mg for all 3 primary endpoints over 6 weeks of treatment. The 30 mg dose has not been studied in osteoarthritis of hands.</p><p style="text-align:justify">In patients with rheumatoid arthritis (RA), etoricoxib 60 mg and 90 mg once daily both provided significant improvements in pain, inflammation, and mobility. In studies evaluating the 60 mg and 90 mg dose, these beneficial effects were maintained over the 12-week treatment periods. In a study evaluating the 60 mg dose compared to the 90 mg dose, etoricoxib 60 mg once daily and 90 mg once daily were both more effective than placebo. The 90 mg dose was superior to the 60 mg dose for Patient Global Assessment of Pain (0-100mm visual analogue scale), with an average improvement of -2.71 mm (95% CI: -4.98 mm, -0.45 mm).</p><p style="text-align:justify">In patients experiencing attacks of acute gouty arthritis, etoricoxib 120 mg once daily over an eight-day treatment period, relieved moderate to extreme joint pain and inflammation comparable to indomethacin 50 mg three times daily. Pain relief was observed as early as four hours after initiation of treatment.</p><p style="text-align:justify">In patients with ankylosing spondylitis, etoricoxib 90 mg once daily provided significant improvements in spine pain, inflammation, stiffness and function. The clinical benefit of etoricoxib was observed as early as the second day of therapy after initiation of treatment and was maintained throughout the 52-week treatment period. In a second study evaluating the 60 mg dose compared to the 90 mg dose, etoricoxib 60 mg daily and 90 mg daily demonstrated similar efficacy compared to naproxen 1,000 mg daily. Among inadequate responders to 60 mg daily for 6 weeks, dose escalation to 90 mg daily improved spinal pain intensity score (0-100 mm visual analogue scale) compared to continuing on 60 mg daily, with an average improvement of -2.70 mm (95% CI: -4.88 mm, -0.52 mm).</p><p style="text-align:justify">In a clinical study evaluating postoperative dental pain, etoricoxib 90 mg was administered once daily for up to three days. In the subgroup of patients with moderate pain at baseline, etoricoxib 90 mg demonstrated a similar analgesic effect to that of ibuprofen 600 mg (16.11 vs. 16.39; P=0.722), and greater than that of paracetamol/codeine 600 mg/60 mg (11.00; P&lt;0.001) and placebo (6.84; P&lt;0.001) as measured by total pain relief over the first 6 hours (TOPAR6). The proportion of patients reporting rescue medication usage within the first 24 hours of dosing was 40.8% for etoricoxib 90 mg, 25.5% for ibuprofen 600 mg Q6h, and 46.7% for paracetamol/codeine 600 mg/60 mg Q6h compared to 76.2% for placebo. In this study, the median onset of action (perceptible pain relief) of 90 mg etoricoxib was 28 minutes after dosing.</p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify"><u>Safety</u></p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify"><u>Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) Programme</u></p><p style="text-align:justify">The MEDAL Programme was a prospectively designed Cardiovascular (CV) Safety Outcomes Programme of pooled data from three randomized, double-blind active comparator controlled trials, the MEDAL study, EDGE II and EDGE.</p><p style="text-align:justify">The MEDAL Study, was an endpoint driven CV Outcomes study in 17,804 OA and 5,700 RA patients treated with etoricoxib 60 (OA) or 90 mg (OA and RA) or diclofenac 150 mg daily for a mean period of 20.3 months (maximum of 42.3 months, median 21.3 months). In this trial, only serious adverse events and discontinuations due to any adverse events were recorded.</p><p style="text-align:justify">The EDGE and EDGE II studies compared the gastrointestinal tolerability of etoricoxib versus diclofenac. The EDGE study included 7,111 OA patients treated with a dose of etoricoxib 90 mg daily (1.5 times the dose recommended for OA) or diclofenac 150 mg daily for a mean period of 9.1 months (maximum 16.6 months, median 11.4 months). The EDGE II study included 4,086 RA patients treated with etoricoxib 90 mg daily or diclofenac 150 mg daily for a mean period of 19.2 months (maximum 33.1 months, median 24 months).</p><p style="text-align:justify">In the pooled MEDAL Programme, 34,701 patients with OA or RA were treated for a mean duration of 17.9 months (maximum 42.3 months, median 16.3 months) with approximately 12,800 patients receiving treatment for more than 24 months. Patients enrolled in the Programme had a wide range of cardiovascular and gastrointestinal risk factors at baseline. Patients with a recent history of myocardial infarction, coronary artery bypass grafting or percutaneous coronary intervention within 6 months preceding enrollment were excluded. Use of gastroprotective agents and low dose aspirin were permitted in the studies.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Overall Safety:</p><p style="text-align:justify">There was no significant difference between etoricoxib and diclofenac in the rate of cardiovascular thrombotic events. Cardiorenal adverse events were observed more frequently with etoricoxib than with diclofenac, and this effect was dose-dependent (see specific results below). Gastrointestinal and hepatic adverse events were observed significantly more frequently with diclofenac than etoricoxib. The incidence of adverse experiences in EDGE and EDGE II and of adverse experiences considered serious or resulting in discontinuation in the MEDAL study was higher with etoricoxib than diclofenac.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Cardiovascular safety results:</p><p style="text-align:justify">The rate of confirmed thrombotic cardiovascular serious adverse events (consisting of cardiac, cerebrovascular, and peripheral vascular events) was comparable between etoricoxib and diclofenac, and data are summarized in the table below. There were no statistically significant differences in thrombotic event rates between etoricoxib and diclofenac across all subgroups analyzed including patient categories across a range of baseline cardiovascular risk. When considered separately, the relative risks for confirmed thrombotic cardiovascular serious adverse events with etoricoxib 60 mg or 90 mg compared with diclofenac 150 mg were similar.</p><table cellspacing="0" cellpadding="0" border="1" style="width:518.25pt"><tbody><tr><td colspan="4" style="vertical-align:top; width:100.0%"><p style="text-align:justify"><strong>Table 2: Rates of Confirmed Thrombotic CV Events (Pooled MEDAL Programme)</strong></p></td></tr><tr><td style="vertical-align:top; width:25.0%">&nbsp;</td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify"><strong>Etoricoxib</strong></p><p style="text-align:justify"><strong>(N=16,819)</strong></p><p style="text-align:justify"><strong>25,836 Patient-Years</strong></p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify"><strong>Diclofenac</strong></p><p style="text-align:justify"><strong>(N=16,483)</strong></p><p style="text-align:justify"><strong>24,766 Patient-Years</strong></p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify"><strong>Between Treatment Comparison</strong></p></td></tr><tr><td style="vertical-align:top; width:25.0%">&nbsp;</td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify"><strong>Rate<sup>&dagger;</sup>&nbsp;(95% CI)</strong></p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify"><strong>Rate<sup>&dagger;</sup>&nbsp;(95% CI)</strong></p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify"><strong>Relative Risk (95% CI)</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top; width:100.0%"><p style="text-align:justify">Confirmed Thrombotic Cardiovascular Serious Adverse Events</p></td></tr><tr><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">Per-protocol</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">1.24 (1.11, 1.38)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">1.30 (1.17, 1.45)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.95 (0.81, 1.11)</p></td></tr><tr><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">Intent-to-treat</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">1.25 (1.14, 1.36)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">1.19 (1.08, 1.30)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">1.05 (0.93, 1.19)</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:100.0%"><p style="text-align:justify">Confirmed Cardiac Events</p></td></tr><tr><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">Per-protocol</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.71 (0.61, 0.82)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.78 (0.68, 0.90)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.90 (0.74, 1.10)</p></td></tr><tr><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">Intent-to-treat</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.69 (0.61, 0.78)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.70 (0.62, 0.79)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.99 (0.84, 1.17)</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:100.0%"><p style="text-align:justify">Confirmed Cerebrovascular Events</p></td></tr><tr><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">Per-protocol</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.34 (0.28, 0.42)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.32 (0.25, 0.40)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">1.08 (0.80, 1.46)</p></td></tr><tr><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">Intent-to-treat</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.33 (0.28, 0.39)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.29 (0.24, 0.35)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">1.12 (0.87, 1.44)</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:100.0%"><p style="text-align:justify">Confirmed Peripheral Vascular Events</p></td></tr><tr><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">Per-protocol</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.20 (0.15, 0.27)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.22 (0.17, 0.29)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.92 (0.63, 1.35)</p></td></tr><tr><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">Intent-to-treat</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.24 (0.20, 0.30)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">0.23 (0.18, 0.28)</p></td><td style="vertical-align:top; width:25.0%"><p style="text-align:justify">1.08 (0.81, 1.44)</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:100.0%"><p style="text-align:justify"><sup>&dagger;</sup>Events per 100 Patient-Years; CI=confidence interval</p><p style="text-align:justify">N=total number of patients included in Per-protocol population</p><p style="text-align:justify">Per-protocol: all events on study therapy or within 14 days of discontinuation (excluded: patients who took &lt; 75% of their study medication or took non-study NSAIDs &gt;10% of the time).</p><p style="text-align:justify">Intent-to-treat: all confirmed events up to the end of the trial (included patients potentially exposed to non-study interventions following discontinuation of study medication). Total number of patients randomised, n= 17,412 on etoricoxib and 17,289 on diclofenac.</p></td></tr></tbody></table><p style="text-align:justify">CV mortality, as well as overall mortality, was similar between the etoricoxib and diclofenac treatment groups.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Cardiorenal Events:</p><p style="text-align:justify">Approximately 50% of patients enrolled in the MEDAL study had a history of hypertension at baseline. In the study, the incidence of discontinuations due to hypertension-related adverse events was statistically significantly higher for etoricoxib than for diclofenac. The incidence of congestive heart failure adverse events (discontinuations and serious events) occurred at similar rates on etoricoxib 60 mg compared to diclofenac 150 mg but was higher for etoricoxib 90 mg compared to diclofenac 150 mg (statistically significant for 90 mg etoricoxib vs. 150 mg diclofenac in MEDAL OA cohort). The incidence of confirmed congestive heart failure adverse events (events that were serious and resulted in hospitalisation or a visit to an emergency department) was non-significantly higher with etoricoxib than diclofenac 150 mg, and this effect was dose-dependent. The incidence of discontinuations due to oedema-related adverse events was higher for etoricoxib than diclofenac 150 mg, and this effect was dose-dependent (statistically significant for etoricoxib 90 mg, but not for etoricoxib 60 mg).</p><p style="text-align:justify">The cardiorenal results for EDGE and EDGE II were consistent with those described for the MEDAL Study.</p><p style="text-align:justify">In the individual MEDAL Programme studies, for etoricoxib (60 mg or 90 mg), the absolute incidence of discontinuation in any treatment group was up to 2.6% for hypertension, up to 1.9% for oedema, and up to 1.1% for congestive heart failure, with higher rates of discontinuation observed with etoricoxib 90 mg than etoricoxib 60 mg.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">MEDAL Programme Gastrointestinal Tolerability Results:</p><p style="text-align:justify">A significantly lower rate of discontinuations of treatment for any clinical (e.g., dyspepsia, abdominal pain, ulcer) GI adverse event was observed with etoricoxib compared with diclofenac within each of the three component studies of the MEDAL Programme. The rates of discontinuations due to adverse clinical GI events per hundred patient-years over the entire period of study were as follows: 3.23 for etoricoxib and 4.96 for diclofenac in the MEDAL Study; 9.12 with etoricoxib and 12.28 with diclofenac in the EDGE study; and 3.71 with etoricoxib and 4.81 with diclofenac in the EDGE II study.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">MEDAL Programme Gastrointestinal Safety Results:</p><p style="text-align:justify">Overall upper GI events were defined as perforations, ulcers and bleeds. The subset of overall upper GI events considered complicated included perforations, obstructions, and complicated bleeding; the subset of upper GI events considered uncomplicated included uncomplicated bleeds and uncomplicated ulcers. A significantly lower rate of overall upper GI events was observed with etoricoxib compared to diclofenac. There was no significant difference between etoricoxib and diclofenac in the rate of complicated events. For the subset of upper GI haemorrhage events (complicated and uncomplicated combined), there was no significant difference between etoricoxib and diclofenac. The upper GI benefit for etoricoxib compared with diclofenac was not statistically significant in patients taking concomitant low-dose aspirin (approximately 33% of patients).</p><p style="text-align:justify">The rates per hundred patient-years of confirmed complicated and uncomplicated upper GI clinical events (perforations, ulcers and bleeds (PUBs)) were 0.67 (95% CI 0.57, 0.77) with etoricoxib and 0.97 (95% CI 0.85, 1.10) with diclofenac, yielding a relative risk of 0.69 (95% CI 0.57, 0.83).</p><p style="text-align:justify">The rate for confirmed upper GI events in elderly patients was evaluated and the largest reduction was observed in patients &ge; 75 years of age (1.35 [95% CI 0.94, 1.87] vs. 2.78 [95% CI 2.14, 3.56] events per hundred patient-years for etoricoxib and diclofenac, respectively.</p><p style="text-align:justify">The rates of confirmed lower GI clinical events (small or large bowel perforation, obstruction, or haemorrhage, (POBs)) were not significantly different between etoricoxib and diclofenac.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">MEDAL Programme Hepatic Safety Results:</p><p style="text-align:justify">Etoricoxib was associated with a statistically significantly lower rate of discontinuations due to hepatic-related adverse experiences than diclofenac. In the pooled MEDAL Programme, 0.3% of patients on etoricoxib and 2.7% of patients on diclofenac discontinued due to hepatic-related adverse experiences. The rate per hundred patient-years was 0.22 on etoricoxib and 1.84 for diclofenac (p-value was &lt;0.001 for etoricoxib vs. diclofenac). However, most hepatic adverse experiences in the MEDAL Programme were non-serious.</p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify"><u>Additional Thrombotic Cardiovascular Safety Data</u></p><p style="text-align:justify">In clinical studies excluding the MEDAL Programme Studies, approximately 3,100 patients were treated with etoricoxib &ge;60 mg daily for 12 weeks or longer. There was no discernible difference in the rate of confirmed serious thrombotic cardiovascular events between patients receiving etoricoxib &ge;60 mg, placebo, or non-naproxen NSAIDs. However, the rate of these events was higher in patients receiving etoricoxib compared with those receiving naproxen 500 mg twice daily. The difference in antiplatelet activity between some COX-1 inhibiting NSAIDs and selective COX-2 inhibitors may be of clinical significance in patients at risk of thrombo-embolic events. Selective COX-2 inhibitors reduce the formation of systemic (and therefore possibly endothelial) prostacyclin without affecting platelet thromboxane. The clinical relevance of these observations has not been established.</p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify"><u>Additional Gastrointestinal Safety Data</u></p><p style="text-align:justify">In two 12-week double-blind endoscopy studies, the cumulative incidence of gastroduodenal ulceration was significantly lower in patients treated with etoricoxib 120 mg once daily than in patients treated with either naproxen 500 mg twice daily or ibuprofen 800 mg three times daily. Etoricoxib had a higher incidence of ulceration as compared to placebo.</p><p style="text-align:justify"><u>&nbsp;</u></p><p style="text-align:justify"><u>Renal Function Study in the Elderly</u></p><p style="text-align:justify">A randomized, double-blind, placebo-controlled, parallel-group study evaluated the effects of 15 days of treatment of etoricoxib (90 mg), celecoxib (200 mg bid), naproxen (500 mg bid) and placebo on urinary sodium excretion, blood pressure, and other renal function parameters in subjects 60 to 85 years of age on a 200-mEq/day sodium diet. Etoricoxib, celecoxib, and naproxen had similar effects on urinary sodium excretion over the 2 weeks of treatment. All active comparators showed an increase relative to placebo with respect to systolic blood pressures; however, etoricoxib was associated with a statistically significant increase at Day 14 when compared to celecoxib and naproxen (mean change from baseline for systolic blood pressure: etoricoxib 7.7 mmHg, celecoxib 2.4 mmHg, naproxen 3.6 mmHg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><em>Absorption</em></p><p style="text-align:justify">Orally administered etoricoxib is well absorbed. The absolute bioavailability is approximately 100%. Following 120 mg once-daily dosing to steady state, the peak plasma concentration (geometric mean C<sub>max</sub>&nbsp;= 3.6 &micro;g/ml) was observed at approximately 1 hour (T<sub>max</sub>) after administration to fasted adults. The geometric mean area under the curve (AUC<sub>0-24hr</sub>) was 37.8 &micro;g&bull;hr/ml. The pharmacokinetics of etoricoxib are linear across the clinical dose range.</p><p style="text-align:justify">Dosing with food (a high-fat meal) had no effect on the extent of absorption of etoricoxib after administration of a 120-mg dose. The rate of absorption was affected, resulting in a 36% decrease in C<sub>max</sub>&nbsp;and an increase in T<sub>max</sub>&nbsp;by 2 hours. These data are not considered clinically significant. In clinical trials, etoricoxib was administered without regard to food intake.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Distribution</em></p><p style="text-align:justify">Etoricoxib is approximately 92% bound to human plasma protein over the range of concentrations of 0.05 to 5 &micro;g/ml. The volume of distribution at steady state (V<sub>dss</sub>) was approximately 1,20l in humans.</p><p style="text-align:justify">Etoricoxib crosses the placenta in rats and rabbits, and the blood-brain barrier in rats.</p><p style="text-align:justify"><em>Biotransformation</em></p><p style="text-align:justify">Etoricoxib is extensively metabolised with &lt;1% of a dose recovered in urine as the parent drug. The major route of metabolism to form the 6&#39;-hydroxymethyl derivative is catalyzed by CYP enzymes. CYP3A4 appears to contribute to the metabolism of etoricoxib&nbsp;<em>in vivo</em>.&nbsp;<em>In vitro</em>&nbsp;studies indicate that CYP2D6, CYP2C9, CYP1A2 and CYP2C19 also can catalyse the main metabolic pathway, but their quantitative roles&nbsp;<em>in vivo</em>&nbsp;have not been studied.</p><p style="text-align:justify">Five metabolites have been identified in man. The principal metabolite is the 6&#39;-carboxylic acid derivative of etoricoxib formed by further oxidation of the 6&#39;-hydroxymethyl derivative. These principal metabolites either demonstrate no measurable activity or are only weakly active as COX-2 inhibitors. None of these metabolites inhibit COX-1.</p><p style="text-align:justify"><em>&nbsp;</em></p><p style="text-align:justify"><em>Elimination</em></p><p style="text-align:justify">Following administration of a single 25-mg radiolabeled intravenous dose of etoricoxib to healthy subjects, 70% of radioactivity was recovered in urine and 20% in faeces, mostly as metabolites. Less than 2% was recovered as unchanged drug.</p><p style="text-align:justify">Elimination of etoricoxib occurs almost exclusively through metabolism followed by renal excretion. Steady state concentrations of etoricoxib are reached within seven days of once daily administration of 120 mg, with an accumulation ratio of approximately 2, corresponding to a half-life of approximately 22 hours. The plasma clearance after a 25-mg intravenous dose is estimated to be approximately 50 ml/min.</p><p style="text-align:justify"><em>Characteristics in patients</em></p><p style="text-align:justify"><em>Elderly patients:&nbsp;</em>Pharmacokinetics in the elderly (65 years of age and older) are similar to those in the young.</p><p style="text-align:justify"><em>Gender:</em>&nbsp;The pharmacokinetics of etoricoxib are similar between men and women.</p><p style="text-align:justify"><em>Hepatic impairment:</em>&nbsp;Patients with mild hepatic dysfunction (Child-Pugh score 5-6) administered etoricoxib 60 mg once daily had an approximately 16% higher mean AUC as compared to healthy subjects given the same regimen. Patients with moderate hepatic dysfunction (Child-Pugh score 7-9) administered etoricoxib 60 mg&nbsp;<strong><em>every other day</em></strong>&nbsp;had similar mean AUC to the healthy subjects given etoricoxib 60 mg once daily; etoricoxib 30 mg once daily has not been studied in this population. There are no clinical or pharmacokinetic data in patients with severe hepatic dysfunction (Child-Pugh score &ge;10). (See sections 4.2 and 4.3.)</p><p style="text-align:justify"><em>Renal impairment:&nbsp;</em>The pharmacokinetics of a single dose of etoricoxib 120 mg in patients with moderate to severe renal insufficiency and patients with end-stage renal disease on haemodialysis were not significantly different from those in healthy subjects. Haemodialysis contributed negligibly to elimination (dialysis clearance approximately 50 ml/min). (See sections 4.3 and 4.4.)</p><p style="text-align:justify"><em>Paediatric patients:</em>&nbsp;The pharmacokinetics of etoricoxib in paediatric patients (&lt;12 years old) have not been studied.</p><p style="text-align:justify">In a pharmacokinetic study (n=16) conducted in adolescents (aged 12 to 17) the pharmacokinetics in adolescents weighing 40 to 60 kg given etoricoxib 60 mg once daily and adolescents &gt;60 kg given etoricoxib 90 mg once daily were similar to the pharmacokinetics in adults given etoricoxib 90 mg once daily. Safety and effectiveness of etoricoxib in paediatric patients have not been established (see section 4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">In preclinical studies, etoricoxib has been demonstrated not to be genotoxic. Etoricoxib was not carcinogenic in mice. Rats developed hepatocellular and thyroid follicular cell adenomas at &gt;2-times the daily human dose [90 mg] based on systemic exposure when dosed daily for approximately two years. Hepatocellular and thyroid follicular cell adenomas observed in rats are considered to be a consequence of rat-specific mechanism related to hepatic CYP enzyme induction. Etoricoxib has not been shown to cause hepatic CYP3A enzyme induction in humans.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In the rat, gastrointestinal toxicity of etoricoxib increased with dose and exposure time. In the 14-week toxicity study etoricoxib caused gastrointestinal ulcers at exposures greater than those seen in man at the therapeutic dose. In the 53- and 106-week toxicity study, gastrointestinal ulcers were also seen at exposures comparable to those seen in man at the therapeutic dose. In dogs, renal and gastrointestinal abnormalities were seen at high exposures.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Etoricoxib was not teratogenic in reproductive toxicity studies conducted in rats at 15 mg/kg/day (this represents approximately 1.5 times the daily human dose [90 mg] based on systemic exposure). In rabbits, a treatment related increase in cardiovascular malformations was observed at exposure levels below the clinical exposure at the daily human dose (90 mg). However no treatment-related external or skeletal foetal malformations were observed. In rats and rabbits, there was a dose dependent increase in post implantation loss at exposures greater than or equal to 1.5 times the human exposure (see sections 4.3 and 4.6).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Etoricoxib is excreted in the milk of lactating rats at concentrations approximately two-fold those in plasma. There was a decrease in pup body weight following exposure of pups to milk from dams administered etoricoxib during lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table cellspacing="0" cellpadding="0" border="0" style="width:63.8%"><tbody><tr><td style="height:21.8pt; width:100.0%"><p>Anhydrous Dibasic Calcium Phosphate (Cal - A)</p></td></tr><tr><td style="height:21.8pt; width:100.0%"><p>Microcrystalline Cellulose PH101</p></td></tr><tr><td style="height:16.6pt; width:100.0%"><p>Povidone K-29/32</p></td></tr><tr><td style="height:20.1pt; width:100.0%"><p>Croscarmellose Sodium</p></td></tr><tr><td style="height:22.35pt; width:100.0%"><p>Magnesium Stearate</p></td></tr><tr><td style="height:21.2pt; width:100.0%"><p>Opadry II Green 32K510003</p></td></tr><tr><td style="height:16.6pt; width:100.0%"><p>Purified&nbsp; water (evaporated during coating)</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:.25in; text-align:justify">Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:.25in; text-align:justify">Alu-Alu blister pack</p><p style="margin-left:.25in; text-align:justify">Pack sizes: 1 X 10&rsquo;s Blister Pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company 
Plot No. ME1:3, Phase V, Industrial City, P.O. Box 6267, Jeddah-21442,
Kingdom of Saudi Arabia.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>